B
CLYM

Bailard’s Climb Bio CLYM Stock Holding History

Bailard’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,800
Closed -$102K – 855
2024
Q4 		$102K Buy
+56,800
New +$206K ﹤0.01% 715

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's CLYM Position: Q1 2025 in Review

Bailard sold out of Climb Bio (CLYM) in Q1 2025, closing a stake of 56,800 shares — an estimated $102K sold.

Bailard first reported a position in CLYM in Q4 2024 and held it in 1 quarter. The position peaked at $102K in Q4 2024. 76 funds tracked by Wall St. Rank hold CLYM as of Q1 2025.

  • Bailard reported no remaining Climb Bio position as of Q1 2025 after selling out during the quarter.
  • Bailard sold 56,800 Climb Bio shares in Q1 2025, an estimated $102K.
  • Bailard first reported a position in Climb Bio in Q4 2024 and held it in 1 quarter.
  • Bailard's Climb Bio position peaked at $102K in Q4 2024.
  • 76 funds tracked by Wall St. Rank held Climb Bio as of Q1 2025.

Based on Bailard's 13F filing for Q1 2025, filed 2 May 2025.